Effect of a strict 'no-talking' policy during intravitreal injection on post-injection endophthalmitis

Ophthalmic Surgery Lasers and Imaging Retina

Volumn 46, Issue 10, 2015, Pages 1028-1034

  Garg, Sunir J ^a   Dollin, Michael ^a   Hsu, Jason ^a   Storey, Philip ^a   Vander, James F ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; AMIKACIN; ATROPINE; BEVACIZUMAB; CEFTAZIDIME; GATIFLOXACIN; LIDOCAINE; MOXIFLOXACIN; PENICILLIN DERIVATIVE; POVIDONE IODINE; PREDNISOLONE ACETATE; RANIBIZUMAB; TOBRAMYCIN; VANCOMYCIN; ANGIOGENESIS INHIBITOR; ANTIINFECTIVE AGENT; HYBRID PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOPHTHALMITIS; ENTEROCOCCUS FAECALIS; FEMALE; HEALTH CARE PLANNING; HEALTH CARE POLICY; HUMAN; LACTOBACILLUS; MAJOR CLINICAL STUDY; MALE; MOUTH FLORA; OBSERVATIONAL STUDY; POST INJECTION ENDOPHTHALMITIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPEECH; STREPTOCOCCUS MITIS; TREATMENT DURATION; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; BACTERIUM; CLINICAL PRACTICE; COMPARATIVE STUDY; EYE INFECTIONS, BACTERIAL; INCIDENCE; INTRAVITREAL DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; MOUTH MUCOSA; PHYSIOLOGY; POLICY; POSTOPERATIVE COMPLICATION; RISK FACTOR;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTI-BACTERIAL AGENTS; BACTERIA; BEVACIZUMAB; ENDOPHTHALMITIS; EYE INFECTIONS, BACTERIAL; FEMALE; HUMANS; INCIDENCE; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; MOUTH MUCOSA; ORGANIZATIONAL POLICY; POSTOPERATIVE COMPLICATIONS; PRACTICE PATTERNS, PHYSICIANS'; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; RISK FACTORS; SPEECH; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84948979095     PISSN: 23258160     EISSN: 23258179     Source Type: Journal    
DOI: 10.3928/23258160-20151027-07     Document Type: Article

References (37)

1. Campbell RJ, Bronskill SE, Bell CM, Paterson JM, Whitehead M, Gill SS. Rapid expansion of intravitreal drug injection procedures, 2000 to 2008: a population-based analysis. Arch Ophthalmol. 2010;128(3):359-362.
2. Williams GA. IVT injections: health policy implications. Rev Ophthalmol. 2014;21:62-64.
3. Shah C P, Garg SJ, Vander J F, et al. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endo-thelial growth factor agents. Ophthalmology. 2011;118(10):2028-2034.
4. McCannell CA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina. 2011;31:654-661.
5. Simunovic M P, Rush RB, Hunyor A P, Chang AA. Endophthalmitis following intravitreal injection versus endophthalmitis following cataract surgery: clinical features, causative organisms and post-treatment outcomes. Br J Ophthalmol. 2012;96(6):862-866.
6. Chen E, Lin MY, Cox J, Brown DM. Endophthalmitis after intra-vitreal injection: the importance of viridans streptococci. Retina. 2011;31(8):1525-1533.
7. Garg SJ, Dollin M, Storey P, et al. Microbial spectrum and outcomes of endophthalmitis after intravitreal injection versus pars plana vitrectomy. Retina. 2015. [Epub ahead of print].
8. Wen JC, McCannel CA, Mochon AB, Garner OB. Bacterial dispersal associated with speech in the setting of intravitreous injections. Arch Ophthalmol. 2011;129(12):1551-1554.
9. Doshi RR, Leng T, Fung AE. Reducing oral fora contamination of in-travitreal injections with face mask or silence. Retina. 2012;32(3):473-476.
10. Friedman DA, Lindquist T P, Mason JO III, McGwin G. Needle contamination in the setting of intravitreal injections. Retina. 2014;34(5):929-934.
11. Shimada H, Hattori T, Mori R, Nakashizuka H, Fujita K, Yuzawa M. Minimizing the endophthalmitis rate following intravitreal injections using 0.25% povidone-iodine irrigation and surgical mask. Graefes Arch Clin Exp Ophthalmol. 2013;251(8):1885-1890.
12. Brynskov T, Kemp H, Sørensen TL. No cases of endophthalmitis after 20,293 intravitreal injections in an operating room setting. Retina. 2014;34(5):951-957.
13. Avery RL, Bakri SJ, Blumenkranz MS, et al. Intravitreal injection technique and monitoring: updated guidelines of an expert panel. Retina. 2014;34 Suppl 12:S1-S18.
14. Goldberg RA, Flynn HW Jr., Isom R F, Miller D, Gonzalez S. An outbreak of streptococcus endophthalmitis after intravitreal injection of bevacizumab. Am J Ophthalmol. 2012;153(2):204-208 e1.
15. Kuriyan AE, Weiss KD, Flynn HW Jr., et al. Endophthalmitis caused by streptococcal species: clinical settings, microbiology, management, and outcomes. Am J Ophthalmol. 2014;157(4):774-780.e1.
16. Chen E, Ho AC, Garg SJ, Brown GC, Kaiser RS. Streptococcus mi-tis endophthalmitis presenting as frosted branch angiitis after intra-vitreal pegaptanib sodium injection. Ophthalmic Surg Lasers Imaging. 2009;40(2):192-194.
17. Gordon D F, Jong BB. Indigenous fora from human saliva. Appl Micro-biol. 1968;16(2):428-429.
18. Molander A, Reit C, Dahlen G, Kvist T. Microbiological status of root-flled teeth with apical periodontitis. Int Endod J. 1998;31(1):1-7.
19. Ahrne S, Nobaek S, Jeppsson B, Adlerberth I, Wold AE, Molin G. The normal Lactobacillus fora of healthy human rectal and oral mucosa. J Appl Microbiol 1998;85(1):88-94.
20. Moss JM, Sanislo SR, Ta CN. A prospective randomized evaluation of topical gatifoxacin on conjunctival fora in patients undergoing intra-vitreal injections. Ophthalmology. 2009;116(8):1498-1501.
21. Milder E, Vander J, Shah C, Garg S. Changes in antibiotic resistance patterns of conjunctival fora due to repeated use of topical antibiotics after intravitreal injection. Ophthalmology. 2012;119(7):1420-1424.
22. Yin V T, Weisbrod DJ, Eng K T, et al. Antibiotic resistance of ocular surface fora with repeated use of a topical antibiotic after intravitreal injection. JAMA Ophthalmol. 2013;131(4):456-461.
23. Kim SJ, Toma HS, Midha NK, Cherney E F, Recchia FM, Doherty TJ. Antibiotic resistance of conjunctiva and nasopharynx evaluation study: a prospective study of patients undergoing intravitreal injections. Ophthalmology. 2010;117(12):2372-2378.
24. Moshfeghi AA, Rosenfeld PJ, Flynn HW Jr., et al. Endophthalmitis after intravitreal vascular [corrected] endothelial growth factor antagonists: a six-year experience at a university referral center. Retina. 2011;31(4):662-668.
25. No authors listed. Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol. 1995;113(12):1479-1496.
26. No authors listed. Microbiologic factors and visual outcome in the en-dophthalmitis vitrectomy study. Am J Ophthalmol. 1996;122(6):830-846.
27. Lalwani GA, Flynn HW Jr., Scott IU, et al. Acute-onset endophthal-mitis after clear corneal cataract surgery (1996-2005). Clinical features, causative organisms, and visual acuity outcomes. Ophthalmology. 2008;115(3):473-476.
28. Schachat A P, Rosenfeld PJ, Liesegang TJ, Stewart M W. Endophthalmi-tis is not a "never event." Ophthalmology. 2012;119(8):1507-1508.
29. Casparis H, Wolfensberger TJ, Becker M, et al. Incidence of presumed endophthalmitis after intravitreal injection performed in the operating room: a retrospective multicenter study. Retina. 2014;34(1):12-17.
30. Abell RG, Kerr NM, Allen P, Vote BJ. Intravitreal injections: is there beneft for a theatre setting? Br J Ophthalmol. 2012;96(12):1474-1478.
31. Tabandeh H, Boscia F, Sborgia A, et al. Endophthalmitis associated with intravitreal injections: offce-based setting and operating room setting. Retina. 2014;34(1):18-23.
32. Friedman DA, Mason JO 3rd, Edmond T, McGwin G Jr. Povidone-iodine contact time and lid speculum use during intravitreal injection. Retina. 2013;33(5):975-981.
33. Fineman MS, Hsu J, Spirn MJ, Kaiser RS. Bimanual assisted eyelid retraction technique for intravitreal injections. Retina. 2013;33(9):1968-1970.
34. Bhatt SS, Stepien KE, Joshi K. Prophylactic antibiotic use after intravit-real injection: effect on endophthalmitis rate. Retina. 2011;31(10):2032-2036.
35. Cheung CS, Wong AW, Lui A, Kertes PJ, Devenyi RG, Lam WC. Incidence of endophthalmitis and use of antibiotic prophylaxis after intra-vitreal injections. Ophthalmology. 2012;119(8):1609-1614.
36. Bhavsar AR, Stockdale CR, Ferris FL, 3rd, Brucker AJ, Bressler NM, Glassman AR. Update on risk of endophthalmitis after intravitreal drug injections and potential impact of elimination of topical antibiotics. Arch Ophthalmol. 2012;130(6):809-810.
37. Storey P, Dollin M, Pitcher J, et al. The role of topical antibiotic prophylaxis to prevent endophthalmitis after intravitreal injection. Ophthalmology. 2014;121(1):283-289.